Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;22(3):175–183. doi: 10.1080/15384047.2020.1834792

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 3. — Summary of imaging scans and timeline of therapy and disease status for Case 3

(a) The recurrent status after surgical resection. (b) The patient then received stereotactic body radiotherapy (SBRT) for the recurrent lesion. (c) MRI scans 4 months after RT revealed progressive enlargement of the recurrent lesion and growth of a new hepatic hilar metastasis. (d) The second SBRT for the recurrent lesion and the new hepatic hilar metastasis. (e) Further disease progression with a left supraclavicular lymph node metastasis detectable in December 2019. (f) The third SBRT for the left supraclavicular lymph node metastasis. (g) The disease stabilized after anti-PD-1 immunotherapy administration. (h) Serum carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) levels with respect to the treatment timeline. (i) Timeline showing therapy and disease status throughout the disease course.